Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy
Sacha Gnjatic(Tisch Hospital), Lisa H. Butterfield(Merck & Co., Inc., Rahway, NJ, USA (United States)), John M. Kirkwood(UPMC Hillman Cancer Center), Marcus O. Butler(University of Toronto), Dolores J. Schendel(Medigene (Germany)), Isabelle Tanneau, Vaios Karanikas(Roche (Switzerland)), Lance D. Miller(Wake Forest University), Laura Rosa Brunet(Immodulon Therapeutics (United Kingdom)), Samir N. Khleif(Georgetown University), Mary L. Disis(University of Washington), Jon M. Wigginton(Bristol-Myers Squibb (United States)), Vincenzo Bronte(University of Verona), Leif Håkansson(Lund University), Jérôme Galon(Délégation Paris 5), Brent A. Hanks(Duke University)
Cited by 239
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
|Immunity|2013|4.7k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k